Myocarditis III: Medical Management

Penicillin is the primary antimicrobial therapy for myocarditis caused by bacterial infections, particularly Group A Streptococcus. The specific antibiotic choice depends on identifying the causative organism. Appropriate antimicrobial therapy addresses the underlying infection and prevents further myocardial damage while supportive measures manage cardiac function.

Bed rest and activity restriction reduce cardiac workload and prevent additional myocardial damage during the acute inflammatory phase. Patients should maintain these restrictions for at least six months or until heart function normalizes. Young patients and athletes require particular adherence to allow complete myocardial recovery before gradually reintroducing physical activity.

ACE inhibitors treat heart failure and manage cardiac enlargement by relaxing blood vessels and improving cardiac output. Beta-blockers manage heart failure and control symptoms associated with an enlarged heart. Both medication classes reduce cardiac workload and improve overall heart function in myocarditis patients experiencing heart failure symptoms.

Diuretics reduce fluid volume and preload, alleviating symptoms of fluid overload. For non-hypotensive patients, intravenous medications like nitroprusside and milrinone decrease systemic vascular resistance, reducing afterload and improving cardiac output. These agents work together to optimize hemodynamics and reduce cardiac strain during acute myocarditis.

Anticoagulation therapy reduces the risk of thromboembolic events in patients with a low ejection fraction by preventing blood clot formation. Myocarditis patients with significantly reduced cardiac function are at increased risk for clot development due to sluggish blood flow. Anticoagulants help prevent serious complications like stroke or pulmonary embolism.

In cases of severe heart failure unresponsive to medical management, intra-aortic balloon pump therapy and ventricular assist devices provide mechanical support. These interventions reduce cardiac workload while allowing the inflamed myocardium to recover. They serve as bridge therapies until the heart regains sufficient function or other definitive treatments become necessary.

Nonsteroidal anti-inflammatory drugs should generally be avoided in myocarditis because they can exacerbate cardiac injury and impair healing, particularly in viral myocarditis. NSAIDs may worsen inflammation and compromise myocardial recovery. Alternative pain management strategies and antiviral therapy for viral etiologies are preferred to protect cardiac function during the acute inflammatory phase.